Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BiomX ( (PHGE) ) has provided an update.
On December 8, 2025, BiomX Israel discontinued its Phase 2b clinical trial of nebulized phage therapy BX004 in cystic fibrosis patients and subsequently entered insolvency proceedings in Israel, with a court-appointed trustee taking control on January 25, 2026. Following the trustee’s termination of BiomX Ltd.’s officers on February 4, 2026, BiomX Inc. deemed this a change of control, deconsolidated the subsidiary as a significant asset disposition, and issued unaudited pro forma financials showing the impact of removing BiomX Israel from its balance sheet and results.
On February 4, 2026, BiomX Ltd.’s CEO Jonathan Solomon and CFO Marina Wolfson, and on February 9, 2026, Chief Development Officer Merav Bassan, were notified that their officer roles at BiomX Ltd. were terminated retroactive to January 25, 2026, though all three remain in their corresponding positions at BiomX Inc. The terminations triggered severance and notice-period obligations, underscoring a restructuring that shifts operational and financial control away from the insolvent Israeli unit while preserving the parent company’s executive leadership structure.
The most recent analyst rating on (PHGE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
The score is primarily constrained by weak financial performance (no meaningful revenue, continued losses, and heavy cash burn with short runway), with additional pressure from dilution/strategic-risk corporate events. Technical momentum is currently strong but looks overextended, while valuation provides limited support due to losses and no dividend.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. is a clinical-stage biotechnology company focused on developing phage-based therapies, including nebulized treatments such as BX004 for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. Its operations have relied heavily on its Israeli subsidiary, BiomX Israel (BiomX Ltd.), where key research and clinical activities have been conducted.
Average Trading Volume: 1,026,972
Technical Sentiment Signal: Sell
Current Market Cap: $6M
For an in-depth examination of PHGE stock, go to TipRanks’ Overview page.